Head and neck diseases

Manel Maños Pujol

PRINCIPAL INVESTIGATORS
  • Lorena Arribas Hortigüela
  • Marc Oliva Bernal
CLINICAL RESEARCHERS
  • Henry Lares Archer
  • Miriam Hamdan Zavarce
  • Julio Nogués Orpí
  • Alicia Lozano Borbalas
  • Francesc Cruellas Taischik
  • Enric Cisa Lluis
  • Laura Rodriguez Bel
  • Mireia Melero Luque
  • Antonio Mari Roig
  • Josep Oriol Bermejo Segu
  • Jordi Tornero Saltó
  • Xavier González Compta
  • Montserrat Gomà Gallego
  • Silvia Cuscó Albors
  • Mònica Cos Domingo
  • María Plana Serrahima
  • Marta Fulla Campi
  • Alejandro Portillo Medina
  • Aina Brunet Garcia
  • Marta Mesalles Ruíz
  • Jesús Brenes Castro
  • Carlos Arranz Obispo
  • Anna Penella Prat
  • Arnaud Morla
  • Ricardo Bartel Arensburg
COLLABORATORS
  • Aleix Rovira Casas
SCIENTIFIC SUPPORT
  • Maria Sospedra Martinez
Cancer
Oncobell

Scientific production

36

PAPERS

Average IF: 4,51

25

LED PAPERS

Average IF: 4,97

4 PUBLICATIONS IN FIRST DECILE

18 PUBLICATIONS IN FIRST QUARTILE

31 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Lorenzo Sanz,L;Lopez Cerda,M;da Silva Diz,V;Artés,MH;Llop,S;Penin,RM;Bermejo,JO et al, Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma, Nat Commun, 2024;15(1):5352-5352, doi:10.1038/s41467-024-49718-8
  • Lopez Cerda,M;Lorenzo Sanz,L;da Silva Diz,V;Llop,S;Penin,RM;Bermejo,JO;Haas,RD et al, IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinoma, J. Exp. Clin. Cancer Res., 2024;43(1):211-211, doi:10.1186/s13046-024-03119-3
  • Cruzado,JM;Sola,A;Pato,ML;Manonelles,A;Varela,C;Setién,FE;Quero Dotor,C et al, Severe ischemia-reperfusion injury induces epigenetic inactivation of LHX1 in kidney progenitor cells after kidney transplantation., Am. J. Transplant., 2024;doi:10.1016/j.ajt.2024.11.003
  • Baliga,S;Abou Foul,AK;Parente,P;Szturz,P;Thariat,J;Shreenivas,A;Nankivell,P et al, Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database, Eur J Cancer, 2024;203114038-114038, doi:10.1016/j.ejca.2024.114038
  • Valenzuela,LM;Gómez Preciado,F;Guiteras,J;Pampols,PA;Gomà,M;Fulladosa,X;Cruzado,JM et al, Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression, J Transl Med, 2024;22(1):421-421, doi:10.1186/s12967-024-05177-9

Research highlights

PROJECTS

1 Granted competitive project
3 Ongoing competitive projects

11 Started clinical trials
39 Ongoing clinical trials

PUBLISHED WORKS

3 Clinical guidelines

Selected projects

  • 20ACL093. A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. GlaxoSmithKline Research & Development Limited;GlaxoSmithKline, S.A.. Budget: 236.335,84€. 2024. PI: Plana Serrahima, María.
  • 2023-491-1. PHASE 1-2 STUDY INVESTIGATING SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF ANTI-TIM-3 MONOCLONAL ANTIBODY BGB-A425 IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS. BEIGENE SWITZERLAND GMBH. Budget: 233.370€. 2023- . PI: OLIVA BERNAL, MARC.
  • 20ACL112. Estudio clínico de fase 2, aleatorizado, abierto y de tres grupos para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) en combinación con pembrolizumab (MK-3475) frente a la quimioterapia de referencia y lenvatinib en monoterapia en parti. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 215.055€. 2020- . PI: Taberna Sanz, Miren.2023-351-1. ENSAYO DE FASE I, ABIERTO, DE ESCALADO DE DOSIS DE BI 1831169 EN MONOTERAPIA Y EN COMBINACIÓN CON EZABENLIMAB EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS O METASTÁSICOS. Boehringer Ingelheim España, S.A. Budget: 201.126€. 2023- . PI: OLIVA BERNAL, MARC.
  • TTCC. MoleculaR profiling and ImmunophEnotyping as preDictors of outcomE in non-metastatic SalIvary Gland carciNomas (REDESIGN). Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC). Budget: 80.000€. 2022-2025. PI: OLIVA BERNAL, MARC.